LIFE aTYR PHARMA INC

Price (delayed)

$4.5

Market cap

$72.29M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.34

Enterprise value

$61.74M

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered ...

Highlights
aTYR PHARMA's quick ratio has soared by 139% YoY and by 98% from the previous quarter
The debt has plunged by 79% YoY and by 9% from the previous quarter
LIFE's EPS is up by 48% year-on-year but it is down by 32% since the previous quarter
The company's gross profit has shrunk by 77% QoQ and by 72% YoY
The revenue has shrunk by 77% QoQ and by 72% YoY

Key stats

What are the main financial stats of LIFE
Market
Shares outstanding
16.06M
Market cap
$72.29M
Enterprise value
$61.74M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.45
Price to sales (P/S)
26.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.83
Earnings
Revenue
$2.39M
EBIT
-$25.13M
EBITDA
-$23.92M
Free cash flow
-$23.22M
Per share
EPS
-$2.34
Free cash flow per share
-$1.65
Book value per share
$3.1
Revenue per share
$0.17
TBVPS
$3.91
Balance sheet
Total assets
$55.13M
Total liabilities
$5.6M
Debt
$2.04M
Equity
$49.7M
Working capital
$47.68M
Liquidity
Debt to equity
0.04
Current ratio
11.71
Quick ratio
11.4
Net debt/EBITDA
0.44
Margins
EBITDA margin
-1,001%
Gross margin
100%
Net margin
-1,051.4%
Operating margin
-1,044.9%
Efficiency
Return on assets
-54.9%
Return on equity
-67.2%
Return on invested capital
-97.6%
Return on capital employed
-49.6%
Return on sales
-1,051.4%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

LIFE stock price

How has the aTYR PHARMA stock price performed over time
Intraday
-3.64%
1 week
-5.26%
1 month
13.64%
1 year
14.8%
YTD
15.98%
QTD
1.12%

Financial performance

How have aTYR PHARMA's revenue and profit performed over time
Revenue
$2.39M
Gross profit
$2.39M
Operating income
-$24.97M
Net income
-$25.13M
Gross margin
100%
Net margin
-1,051.4%
The company's gross profit has shrunk by 77% QoQ and by 72% YoY
The revenue has shrunk by 77% QoQ and by 72% YoY
aTYR PHARMA's operating income has plunged by 64% YoY and by 57% from the previous quarter
The net income has plunged by 60% YoY and by 55% from the previous quarter

Growth

What is aTYR PHARMA's growth rate over time

Valuation

What is aTYR PHARMA stock price valuation
P/E
N/A
P/B
1.45
P/S
26.56
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
25.83
LIFE's EPS is up by 48% year-on-year but it is down by 32% since the previous quarter
The company's equity has surged by 57% QoQ and by 18% YoY
LIFE's P/B is 45% above its 5-year quarterly average of 1.0 and 21% above its last 4 quarters average of 1.2
LIFE's P/S is 180% above its last 4 quarters average of 9.5
The revenue has shrunk by 77% QoQ and by 72% YoY

Efficiency

How efficient is aTYR PHARMA business performance
The company's return on invested capital has shrunk by 66% YoY and by 16% QoQ
The ROA has plunged by 60% YoY and by 54% from the previous quarter
The return on equity has declined by 47% since the previous quarter and by 28% year-on-year

Dividends

What is LIFE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LIFE.

Financial health

How did aTYR PHARMA financials performed over time
The current ratio has soared by 143% YoY and by 93% from the previous quarter
aTYR PHARMA's quick ratio has soared by 139% YoY and by 98% from the previous quarter
The debt is 96% less than the equity
LIFE's debt to equity has plunged by 83% YoY and by 43% from the previous quarter
The debt has plunged by 79% YoY and by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.